| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d55444126b55e1edeb40523a4818da76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_825ca9aa6673698a03356085039c637f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-72 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-72 |
| filingDate |
2008-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48e4f9691566bdcdfa05d190207078eb |
| publicationDate |
2008-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008124824-A1 |
| titleOfInvention |
Dosages and methods for the treatment of cancer |
| abstract |
In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a Cmax of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9017416-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10966837-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010044686-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9649193-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9283079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9956081-B2 |
| priorityDate |
2007-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |